Form 4 holding
Chief Financial Officer
Niagen Bioscience, Inc.
- Security class
- Common Stock
- Shares / value
- 11,627
- Estimated value
- $37,090
- Report date
- 30 Jun 2026
- Price
- $3.19
- Ownership
- Direct
Ozan Pamir
Insider Reports History
- Reporting-owner location
- San Francisco, CA
- Latest reporting-owner signature
-
/s/ Jeong James Lee, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Ozan Pamir
Form 4 holding
Chief Financial Officer
Niagen Bioscience, Inc.
- Security class
- Common Stock
- Shares / value
- 2,220
- Estimated value
- $7,083
- Report date
- 30 Jun 2026
- Price
- $3.19
- Ownership
- The reported securities are held by the reporting person's spouse.
Form 4 holding
CFO
180 Life Sciences Corp.
- Security class
- Common Stock
- Shares / value
- 8,983
- Estimated value
- $1,689
- Report date
- 04 Sep 2023
- Price
- $0.1880
- Ownership
- Direct
Form 4 holding
Chief Financial Officer
Niagen Bioscience, Inc.
- Security class
- Employee Stock Options (right to buy)
- Shares / value
- 62,131
- Estimated value
- Report date
- 19 Feb 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
CFO
180 Life Sciences Corp.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 15,000
- Estimated value
- Report date
- 04 Sep 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Ozan Pamir
4
NAGE
Niagen Bioscience, Inc.
- Report period
- 30 Jun 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 08 Jul 2026, 17:17
- Role
- Chief Financial Officer
- Next action
- Open filing details
4
NAGE
Niagen Bioscience, Inc.
- Report period
- 19 Feb 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 24 Feb 2026, 16:46
- Role
- Chief Financial Officer
- Next action
- Open filing details
4
NAGE
Niagen Bioscience, Inc.
- Report period
- 14 Nov 2025
- Transactions
- 2
- Transaction value
- +$45,616
- Accepted by SEC
- 17 Nov 2025, 08:23
- Role
- Chief Financial Officer
- Next action
- Open filing details
4
NAGE
ChromaDex Corp.
- Report period
- 12 Feb 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 14 Feb 2025, 18:18
- Role
- Chief Financial Officer
- Next action
- Open filing details
4
NAGE
ChromaDex Corp.
- Report period
- 22 Nov 2024
- Transactions
- 1
- Transaction value
- +$21,397
- Accepted by SEC
- 25 Nov 2024, 07:28
- Role
- Chief Financial Officer
- Next action
- Open filing details
4
NAGE
ChromaDex Corp.
- Report period
- 21 Oct 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 23 Oct 2024, 17:04
- Role
- Chief Financial Officer
- Next action
- Open filing details
3
NAGE
ChromaDex Corp.
- Report period
- 21 Oct 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 23 Oct 2024, 17:03
- Role
- Chief Financial Officer
- Next action
- Open filing details
4
ATNF
180 Life Sciences Corp.
- Report period
- 04 Sep 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 06 Sep 2023, 18:30
- Role
- CFO
- Next action
- Open filing details
4
ATNF
180 Life Sciences Corp.
- Report period
- 18 May 2023
- Transactions
- 1
- Transaction value
- +$5,214
- Accepted by SEC
- 19 May 2023, 08:30
- Role
- CFO
- Next action
- Open filing details
4
ATNF
180 Life Sciences Corp.
- Report period
- 10 Dec 2021
- Transactions
- 1
- Transaction value
- +$14,706
- Accepted by SEC
- 13 Dec 2021, 07:31
- Role
- Interim CFO
- Next action
- Open filing details